Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From William Looney
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
Insights from Gates Medical Research Institute CEO Dr. Penny Heaton.
In Vivo visits Gates Medical Research Institute CEO Dr. Penny Heaton to review its first pipeline of drugs and vaccines to attack four of the world’s biggest killers: TB, malaria, enteric diseases and other conditions affecting maternal, newborn and child health.
Big pharma is facing a difficult US competitive landscape as its traditional customers realign to build their own redoubts of size, scale and reach.
Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.
Amgen’s Judy Gawlik Brown is using her finance and consumer health background to make the big biotech’s message more authentic and accessible – a brisk reset against today’s disconnected world of alternative facts.